How do we pitch a clean-exit buyer on our highly regulated health-tech business when our medical writing operations rely heavily on custom LLM pipelines, without triggering their compliance department's automatic rejection of AI?

Question

Tyler Smith · Accepted Answer

When prepping your regulated business for a clean exit, buyers will perform deep due diligence on your automated workflows. If their legal team smells unverified AI in your medical or regulatory pipelines, they will run. You must reposition your automated operations from an autonomous AI liability to a strictly audited human-supervised workflow. Start by updating your Accountability Chart. Every single node where an LLM touches data must have a human seat directly accountable for the output. This is not just a general process; it is a clear role on your chart with measurable metrics on your Scorecard. Next, document your compliance guardrails as a core asset. Your V/TO® should outline how your proprietary workflow relies on human-in-the-loop engineering. Show the buyer that your AI is not acting as the decision-maker, but rather as an operational super-compiler. The value you are selling is not the software itself, but your proprietary process for ensuring the software behaves. In your Level 10 Meeting™, run these objections through the IDS® process to build an audit trail. Show that your regulatory compliance is actually stronger because your human operators are auditing structured machine logs rather than starting from scratch. When a buyer realizes your system reduces human error while maintaining human accountability, they will pay a premium.